# A Study of CS1003 in Subjects With Advanced Solid Tumors

> **NCT03475251** · PHASE1 · COMPLETED · sponsor: **CStone Pharmaceuticals** · enrollment: 108 (actual)

## Conditions studied

- Advanced Cancer

## Interventions

- **BIOLOGICAL:** CS1003
- **BIOLOGICAL:** CS1003
- **DRUG:** Regorafenib

## Key facts

- **NCT ID:** NCT03475251
- **Lead sponsor:** CStone Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-05-09
- **Primary completion:** 2021-05-31
- **Final completion:** 2021-05-31
- **Target enrollment:** 108 (ACTUAL)
- **Last updated:** 2022-02-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03475251

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03475251, "A Study of CS1003 in Subjects With Advanced Solid Tumors". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03475251. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*